DCTH Delcath Corp: Price-to-Projected Revenue Ratio
The forward P/S of Delcath Systems, Inc. (DCTH) reflects market expectations, where the 8.30 mark serves as the current benchmark. Delcath Systems, Inc. (DCTH) is advancing oncotherapy through clinical partnerships and the strategic acquisition of patents. Growth is driven by the implementation of the Hepzato system and the scaling of its medical center network. Laboratory operations do not harm the environment, strictly adhering to established environmental standards.
Analytical breakdowns for Delcath Corp (DCTH)
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- business debt structure and liquidity details:
Total Debt to Equity Ratio Delcath Systems, Inc.|DCTH - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital Delcath Systems, Inc.|DCTH - Aggregate Debt Obligations|Debt to Book Value Delcath Corp|DCTH - Company Long-Term Loans and Borrowings|Company Short-Term Debt Delcath Systems|Quick Liquidity Indicator delcath.com
- financial results and valuation multiples details:
DCTH - Company Net Income|Expected Profit Delcath Systems, Inc.|DCTH - Business Payback Period|Projected Price to Earnings Delcath|DCTH - Company Value to Earnings Growth Ratio|EV/EBITDA Multiple Delcath Corp|DCTH - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Delcath Systems|DCTH - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last twelve months delcath.com|DCTH - Expected net earnings per share growth this year|Expected earnings per share growth for next year Delcath Systems, Inc.
- sales and revenue data:
Summary company analysis:Delcath Systems (DCTH)
The forward P/S ratio measures the current market value of Delcath Systems, Inc. (DCTH) relative to expected revenue, reflecting the degree of investor optimism priced in. By analyzing this forward price-to-sales multiple chart, one can assess the fairness of the valuation for Delcath Systems, Inc. (DCTH) during the organic rollout of its liver therapy system, a period where the absence of M&A activity makes future sales dynamics the sole driver of capitalization growth.
Key competitors
Forward P/S Multiple ONC (BeiGene)|Halozyme Therapeutics, Inc. (HALO) - Market Cap to Future Revenue Ratio|RVMD - Price-to-Projected Revenue Ratio|AAPG: Price-to-Projected Revenue Ratio|CGON: Forward P/S Multiple|Forward Price-to-Revenue Multiple urogen.com|BCAX (Bicara Therapeutics) - Forward P/S Multiple|Forward P/S Multiple Personalis Inc|Forward Price-to-Revenue Multiple ERAS (Erasca Corp)|Price to Expected Revenue Ratio YMAB|Forward P/S Multiple AURA (Aura Biosciences, Inc.)|Forward Price to Sales CADL|ARAY: Forward Price-to-Revenue Multiple|Forward Price to Sales SLS (SELLAS Life Sciences)|Actuate Therapeutics, Inc (ACTU) - Price-to-Projected Revenue Ratio|CTOR - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple HURA|Market Cap to Future Revenue Ratio protaratx.com TARA|Price-to-Projected Revenue Ratio Fate Therapeutics (FATE)|Market Cap to Expected Sales Ratio aadibio.com|TScan Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CSBR (Champions Oncology Inc)|XBiotech USA - Forward P/S Multiple|Market Cap to Future Revenue Ratio CEL-SCI Corporation|OS Therapies (OSTX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple radiopharmtheranostics.com|Price-to-Projected Revenue Ratio Artiva Biotherapeutics Inc.|Adlai Nortye Limited (ANL) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple VERU (Veru Inc.)|TPST (tempesttx.com) - Forward Price to Sales|Forward P/S Multiple XLO (Xilio Therapeutics)|Market Cap to Expected Sales Ratio Renovaro Biosciences (RENB)|MURA - Price-to-Projected Revenue Ratio|KAPA (Kairos Pharma Ltd) - Market Cap to Projected Revenue|OKUR: Forward P/S Multiple|Forward Price-to-Revenue Multiple CytoMed Therapeutics Limited|Forward Price-to-Revenue Multiple CRIS|Apollomics Corp (APLM) - Market Cap to Expected Sales Ratio|Forward P/S Multiple THAR|advanbiomed.com - Market Cap to Projected Revenue|Forward P/S Multiple GNPX (Genprex, Inc.)|CLDI - Forward Price-to-Revenue Multiple|SBFM: Forward Price-to-Revenue Multiple|Xenetic Biosciences - Price to Expected Revenue Ratio|SLRX: Forward P/S Multiple|Kitov Pharma - Forward Price to Sales|AONC (American Oncology Network Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple beigene.com (BGNE)|Forward P/S Multiple CKPT|Forward P/S Multiple elevationoncology.com (ELEV)|Price-to-Projected Revenue Ratio iCAD ICAD|IKNA: Market Cap to Projected Revenue|Notable Labs, Ltd. - Forward P/S Multiple|Viracta Therapeutics (VIRX) - Forward Price-to-Revenue Multiple|MOR: Forward P/S Multiple|Market Cap to Future Revenue Ratio NAYA Biosciences Inc (NAYA)|Price-to-Projected Revenue Ratio Ascentage Pharma Group Ltd
